All Updates

All Updates

icon
Filter
Partnerships
ALZpath partners with Roche to develop and commercialize Alzheimer's disease diagnostic test
Precision Medicine
Jun 10, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Jun 20, 2024
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Jun 20, 2024
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Jun 20, 2024
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Jun 20, 2024
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Jun 20, 2024
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Jun 20, 2024
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Jun 20, 2024
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Jun 20, 2024
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Jun 20, 2024
Precision Medicine

Precision Medicine

Jun 10, 2024

ALZpath partners with Roche to develop and commercialize Alzheimer's disease diagnostic test

Partnerships

  • ALZpath has partnered with Roche to provide its pTau217 antibody, a critical biomarker in detecting the presence of Alzheimer's disease in blood, to be used in the development and commercialization of Roche's Alzheimer's disease diagnostic blood test, Roche pTau217.

  • The blood assay developed using the antibody has reportedly shown results that are equally accurate and reliable as PET imaging or cerebrospinal fluid (CSF) testing, with a lower cost and non-invasive procedure. The test, recently granted FDA Breakthrough Device designation, will be commercialized as part of an ongoing partnership with Eli Lilly. It is planned to be distributed via the Roche Elecsys platform. 

  • ALZpath is a biotechnology company specializing in developing diagnostic solutions for Alzheimer's disease. The company focuses on early and accurate diagnosis using blood-based biomarkers. Its primary product is ALZpathDx, which measures phosphorylated tau at threonine 217 (pTau217) in the blood, a key indicator of Alzheimer’s disease that can be detected before cognitive symptoms appear. This diagnostic tool is designed to be simple, accessible, cost-effective, and less invasive than traditional methods.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.